Oncology Clinical Trials in Houston, TX
As of September 2026, 841 paid clinical trials are recruiting for Oncology in Houston, Texas. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
Newly added in Houston
Posted to ClinicalTrials.gov within the last 60 days — these studies are just starting to recruit.
A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation
844 clinical trials for Oncology
·Clear filters·Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Top Research Study Locations in Houston
Researchers run research studies in Houston, TX at 25 active sites. The clinics below currently host the largest number of recruiting studies — each name is followed by the conditions they focus on most.
| Site | Specializes in | Active trials |
|---|---|---|
| MD Anderson Cancer Center | Colorectal Cancer, Breast Cancer, Ovarian Cancer | 407 |
| M D Anderson Cancer Center | Hematopoietic and Lymphoid Cell Neoplasm, Acute Myeloid Leukemia, Malignant Solid Neoplasm | 252 |
| Baylor College of Medicine | Epilepsy, Heart Failure, Anxiety Disorders | 191 |
| The University of Texas Health Science Center at Houston | Cluster Headache, HIV Infections, Systemic Sclerosis | 183 |
| The University of Texas MD Anderson Cancer Center | Advanced Solid Tumor, Breast Cancer, Colorectal Cancer | 132 |
| Houston Methodist Hospital | Acute Respiratory Distress Syndrome, ARDS, ARDS (Acute Respiratory Distress Syndrome) | 130 |
| Texas Children's Hospital | Diffuse Intrinsic Pontine Glioma, High Grade Glioma, WHO Grade III Glioma | 111 |
| The University of Texas M. D. Anderson Cancer Center | Cancer, Breast Cancer, Prostate Cancer | 86 |
| University of Texas MD Anderson Cancer Center | Breast Cancer, Non-small Cell Lung Cancer, Chronic Lymphocytic Leukemia | 86 |
| UT MD Anderson Cancer Center | Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm, Advanced Malignant Solid Neoplasm | 71 |
| Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center | Acute Myeloid Leukemia, Malignant Solid Neoplasm, Anatomic Stage II Breast Cancer AJCC v8 | 55 |
| MD Anderson | Myelodysplastic Syndromes, Myelofibrosis, Acute Myeloid Leukemia | 38 |
| Houston Methodist | Heart Failure, Cardiovascular Diseases, Heart Valve Diseases | 32 |
| Michael E. DeBakey VA Medical Center, Houston, TX | Spinal Cord Injury, Metastatic Prostate Cancer, Stress Disorders, Post-Traumatic | 31 |
| University of Texas Health Science Center at Houston | Infant, Small for Gestational Age, Infant, Low Birth Weight, Infant, Newborn | 28 |
| UT MD Anderson | Breast Cancer, AML, Acute Myeloid Leukemia | 26 |
| Ben Taub General Hospital | Acute Myeloid Leukemia, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | 25 |
| Houston Methodist Research Institute | Hepatocellular Carcinoma, AAA, AAA - Abdominal Aortic Aneurysm | 23 |
| GSK Investigational Site | Chickenpox, HIV Infections, Gastrointestinal Neoplasms | 21 |
| The University of Texas M.D. Anderson Cancer Center | Advanced Breast Cancer, Breast Cancer, Metastatic Breast Cancer | 17 |
| Houston Methodist West Hospital | Anatomic Stage II Breast Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, AL Amyloidosis | 16 |
| UTHealth Houston | Acute Suicidal Depression (ASD), Charcot-Marie-Tooth Disease Type 2D, Emergency Department Visits | 16 |
| Michael E. DeBakey VA Medical Center | Gulf War Syndrome, Adult Growth Hormone Deficiency, Alzheimer Disease | 14 |
| Memorial Hermann Texas Medical Center | Acute Kidney Injury, Ischemic Stroke, Ovarian Carcinoma | 14 |
| Oncology Consultants | Breast Cancer, Esophageal Cancer, Advanced Cancer | 14 |
Active & Upcoming Studies in Houston (2026)
Recruiting trials in Houston grouped by therapeutic area, drawn from ClinicalTrials.gov. Each bucket shows the most recent example studies.
Cancer & tumors (1,171 active studies)
- A Phase 1 Open-Label, Dose-Ranging Safety and Pharmacokinetics Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML) · Phase 1, Phase 2 · M.D. Anderson Cancer Center
- Randomized Phase 2 Study Of Epcoritamab Vs Watch And Wait InPatients With Previously Untreated Low Tumor Burden FollicularLymphoma · Phase 2 · M.D. Anderson Cancer Center
Neurology & pain (140 active studies)
- Neuro-Intermuscular Coordination Enhancement (NICE) Rehabilitation Through Human-Machine Interaction in Chronic Stroke · EARLY_Phase 1 · University of Houston
- Prospective Randomized Study of TPS + CBT VS TPS Alone: Readmission, Opioid Use, and Chronic Pain · M.D. Anderson Cancer Center
Diabetes & metabolic (105 active studies)
- Benefits of Insoles With Real-Time Alert and Foot Self-Care Education · Texas Woman's University
- Continued Access to the Endogenex System for Participants in the ReCET Pivotal Study · Endogenex, Inc.
Cardiovascular (103 active studies)
- HiCM-188 Cell Therapy in Adults With Advanced Heart Failure Undergoing Heart Bypass Surgery · Phase 1, Phase 2 · HELP Therapeutics Co., Ltd.
- A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event · Phase 2 · Eli Lilly and Company
Mental health & behavior (80 active studies)
- ACT for Veterans With IBD and Mental Health Challenges · VA Office of Research and Development
- Pilot Randomized Trial of BA-GSH in VA PC-MHI · VA Office of Research and Development
Pediatric (45 active studies)
- Food is Medicine in Survivorship: Examining the Feasibility and Impact of a Scalable Food Delivery and Culinary Medicine Program (FoodiiS) Among Pediatric Cancer Survivors and Their Families · M.D. Anderson Cancer Center
- Feasibility Trial of the Womb Watch Smartphone App To Assess Fetal Movements · Kenneth Moise MD
HIV / STI (34 active studies)
- Improving HIV Prevention and Substance Use Post-Sexual Assault Services · The University of Texas Health Science Center, Houston
- A Study to Evaluate the Safety and Antiviral Activity of Two Human Monoclonal Antibodies (VRC07-523LS and PGT121.414.LS) During Analytic Treatment Interruption in Participants Living With HIV Who Initiated ART During Acute/Early HIV-1 Infection · Phase 1 · National Institute of Allergy and Infectious Diseases (NIAID)
Vaccines (26 active studies)
- A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine · Phase 1 · National Institute of Allergy and Infectious Diseases (NIAID)
- A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Given to Healthy Children 4 to 6 Years of Age · Phase 3 · GlaxoSmithKline
Eye & vision (24 active studies)
- Treating Contact Lens Discomfort With Varenicline Solution Nasal Spray 0.03mg · Ocular Aesthetics, LLC dba Ocular Clinical Trials
- A Comparative, Randomized, Investigator-blind, Active-controlled, Parallel-group, Multicenter, Clinical Endpoint Study · Phase 3 · YS Life Science Co., Ltd.
Common conditions studied in Houston
- Breast Cancer (76 active studies)
- Acute Myeloid Leukemia (52 active studies)
- Advanced Solid Tumor (52 active studies)
- Colorectal Cancer (46 active studies)
- Ovarian Cancer (46 active studies)
- Prostate Cancer (43 active studies)
Leading research sponsors in Houston
- M.D. Anderson Cancer Center
- The University of Texas Health Science Center, Houston
- Baylor College of Medicine
- AstraZeneca
- The Methodist Hospital Research Institute
Frequently asked questions
How many paid clinical trials are currently recruiting in Houston?
There are approximately 3,045 recruiting clinical trials in Houston, Texas listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Houston pay participants?
Most recruiting trials in Houston compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Houston?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Houston?
The most common conditions under active study in Houston include Breast Cancer (76), Acute Myeloid Leukemia (52), Advanced Solid Tumor (52), Colorectal Cancer (46), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Houston?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Houston on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Houston?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Houston?
Recruiting research sites in Houston include MD Anderson Cancer Center, M D Anderson Cancer Center, Baylor College of Medicine, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Houston right now?
The largest active categories in Houston are Cancer & tumors (1,171), Neurology & pain (140), Diabetes & metabolic (105). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.